Metabolic & Cardiometabolic
bariatric surgery decreases cardiovascular events
In plain terms: Does bariatric surgery reduce cardiovascular events?
Strong support Metabolic & Cardiometabolic 🔬 Includes disconfirming
Part of: 🩺 bariatric / metabolic surgery
RefutedContestedStrong support
consensus score 0.86
Yes—observational cohorts and meta-analyses consistently show ~40-50% lower MACE/MI, though no dedicated CV-outcome RCT and residual confounding remain.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
15 support 1 contradict 0 tested null 2 mixed · 18 sources, 16 independent groups
What the evidence shows
Bariatric surgery is associated with substantially fewer cardiovascular events, with myocardial infarction at a hazard ratio near 0.61, heart failure 0.55 and stroke 0.80, and the Swedish Obese Subjects registry agrees in people who had diabetes at baseline. No trial used cardiovascular events as its primary endpoint, so selection confounding remains.
The evidence (22)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Sjöström L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden Å, Bouchard C, Carlsson B, Karason K, Lönroth H, Näslund I, Sjöström E, Taube M, Wedel H, Svensson PA, Sjöholm K, Carlsson LM 2014 · JAMA | observational | supports | high | Among Swedish Obese Subjects participants who had type 2 diabetes at baseline (343 surgery, 260 usual care), macrovascular complications recorded in national registers over a median 18 years occurred at 31.7 per 1000 person-years after surgery versus 44.2 in controls (hazard ratio 0.68, 95% CI 0.54-0.85). Microvascular complications fell further, 20.6 versus 41.8 per 1000 person-years (hazard ratio 0.44). Surgery was chosen by patients rather than assigned, and the authors say the findings need confirmation in randomised trials. |
| Cordova F, Málaga N 2026 · Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery | meta-analysis | supports | moderate | Systematic review/meta-analysis (GRADE-assessed) of 5 cohort studies (N=39,569) comparing bariatric surgery vs GLP-1RA; surgery associated with 43% lower mortality (HR 0.57), 35% lower MACE (HR 0.65), and 55% lower heart failure risk (HR 0. |
| Kim Y, Kim KH, Lee SH, Moon Y, Oh Y, Seo KW 2026 · J Metab Bariatr Surg | observational | supports | low | Narrative review of long-term outcomes after metabolic and bariatric surgery. From the studies it summarizes, surgery is followed by lower all-cause mortality and fewer cardiovascular events than usual care: in the Swedish Obese Subjects cohort adjusted median life expectancy was 3.0 years longer after surgery, and a 2022 systematic review and meta-analysis reported lower all-cause and cardiovascular mortality and lower rates of heart failure, myocardial infarction and stroke. The review runs no analysis of its own and reports no pooled effect size. |
| Mahmoud AK, Awad K, Sheashaa H, Mohammed A, Farina JM, Pereyra M, Scalia IG, Hafez A, Senjab A, Ibrahim R, Mital R, Shipman J, Alsidawi S, Lester SJ, Ommen SR, Geske JB, Patten R, Ayoub C, Arsanjani R 2026 · American heart journal plus : cardiology research and practice | observational | supports | moderate | TriNetX propensity-matched cohort (2568/arm) of obese HCM patients; bariatric surgery associated with reduced all-cause mortality (HR 0.40, 95% CI 0.27-0.61) and acute heart failure hospitalization (HR 0.76) vs non-surgical matched controls |
| Villelabeitia IK, Cohen R, le Roux CW 2026 · Heart (British Cardiac Society) | observational | supports | low | Narrative review states MBS evidence is 'dominated by large observational cohorts and meta-analyses' showing durable weight loss and lower observed rates of MACE, heart failure, and all-cause mortality vs non-surgical care, with causal infe |
| Zhou X, Yu J, Li L, Gloy VL, Nordmann A, Tiboni M, Li Y, Sun X 2016 · Obes Surg | meta-analysis | supports | moderate | Landmark systematic review found bariatric surgery associated with reduced cardiovascular events versus non-surgical treatment in obese patients. |
| Chhabra KR, Gencerliler N, Orandi BJ, Wang VH, Kozato A, Surapaneni A, Grams M, Mukhopadhyay A, Shin JI, Ren-Fielding C, Parikh M, Zhang DS 2026 · Obesity (Silver Spring, Md.) | observational | supports | moderate | MarketScan claims cohort (n=6748) comparing semaglutide vs sleeve gastrectomy/gastric bypass in T2D+obesity; relative to semaglutide, gastric bypass had fewer MACE (HR 0.71, 95% CI 0.59-0.88) and sleeve gastrectomy fewer MACE (HR 0.79, 95% |
| Salib A, Hay M, Abrahams T, Muthalaly R, Aldous E, Tu H, Nerlekar N 2026 · Am J Cardiol | meta-analysis | supports | high | MI HR 0.61, new heart failure HR 0.55, stroke HR 0.80, AF HR 0.70—broad CV benefit, consistent across procedures. |
| Shekouh D, Behboodi M, Varmazyar M, Khodadadiyan A, Jochin P, Bazrafshan Drissi H 2026 · Obesity surgery | meta-analysis | supports | moderate | PRISMA systematic review/meta-analysis of 6 cohort studies (n>282,450) comparing MBS vs GLP-1RA; MBS associated with lower CVD prevalence (RR 0.63, 95% CI 0.49-0.81) and heart failure (RR 0.50) vs GLP-1RA. |
| Wilkinson TJ, Goldney J, Yates T, Henson J, Zaccardi F, Khunti K, Webb D, Papamargaritis D, Davies MJ 2026 · Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association | observational | supports | moderate | TriNetX propensity-matched cohorts of T2D+CKD patients; bariatric surgery (n=2603) vs weight-neutral DPP4i control associated with reduced myocardial infarction (HR 0.45), stroke (HR 0.57), and all-cause mortality (HR 0.68). |
| Yan G, Wang J, Zhang J, Gao K, Zhao Q, Xu X 2019 · PLoS One | meta-analysis | supports | moderate | 4 RCTs + 6 cohorts: macrovascular complications RR 0.43, CV events HR 0.52, MI RR 0.40 over >5yr. |
| Chen X, Zhang X, Xiang X, Fang X, Wei F, Feng S 2025 · Int J Obes | meta-analysis | supports | moderate | Umbrella review whose units are syntheses: 'We conducted a systematic search, extraction, and analysis of data from published systematic reviews and meta-analyses exploring the associations between various weight control interventions and all-cause mortality as well as cardiovascular outcomes'. Conclusion restates them: 'Bariatric surgery was consistently associated with reduced risks for all cardiovascular outcomes except atrial fibrillation.' Review — zero weight. |
| Chadwick J, Sivamani C, Lakshmi S, Baskaran V, N L S, Ayyasamy L, Parasuraman G, Bagepally BS 2026 · Obesity surgery | meta-analysis | supports | moderate | PROSPERO-registered systematic review/meta-analysis of RCTs and observational studies comparing MBS vs GLP-1RA in obesity+T2D; MBS showed ~52% relative risk reduction in MACE and lower all-cause mortality vs GLP-1RA, certainty moderate. |
| Yang W, Zhan M, Li Z, Sun X, Zhang K 2023 · Obes Surg | meta-analysis | supports | moderate | Matched/prospective cohorts (122k) diabetic obese: significantly reduced MACE after metabolic/bariatric surgery. |
| Ibrahim R, Han W, Wang W, Kau E, Said N, Forst B, Pham HN, Abdelnabi M, Salih M, Ali NB, Farina J, Lester SJ, Lee K, Ayoub C, Arsanjani R 2025 · Journal of the American Heart Association | observational | mixed | moderate | TriNetX retrospective cohort (2747/arm) of obese HFpEF patients; GLP-1RA therapy associated with lower acute HF events, all-cause death (HR 0.71 favoring GLP-1RA), and hospitalizations than bariatric surgery, with similar MI/stroke rates be |
| Mahmoud AK, Awad K, Sheashaa H, Kandil O, Farina JM, Ibrahim R, Abdelnabi M, Allam M, Mital R, Shipman J, Alsidawi S, Lester SJ, Ommen SR, Geske JB, Patten R, Ayoub C, Arsanjani R 2026 · European heart journal. Quality of care & clinical outcomes | observational | contradicts | moderate | Propensity-matched cohort of obese HCM patients; over 24 months, GLP-1RA users had lower all-cause mortality (HR vs BS 0.46) and fewer composite cardiovascular outcomes (HR 0.60) than bariatric surgery patients. |
| Qazi SU, Shuja MH, Shakil F, Ansari HUH, Khan LA, Aziz AA, Dang AK, Hassan OU, Farhan M, Ahmed R, Hall ME 2026 · Obes Surg | meta-analysis | mixed | moderate | In pre-existing CVD: MACE HR 0.55 significant, but MI (HR 0.53) and cerebrovascular events (HR 0.99) non-significant—benefit not uniform. |
| Tong J, Cao Y, Han Y, Wang W, Zhu C, Yuan H, Zhu S, Lu Y, Zhu L 2026 · Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery | meta-analysis | supports | moderate | Systematic review/meta-analysis of 15 controlled studies comparing metabolic-bariatric surgery (MBS) vs pharmacological therapy in T2D+obesity; MBS reduced MACE, benefit sustained/growing to 5 years (OR 0.66, 95% CI 0.59-0.73). |
| Tang B, Zhang Y, Wang Y, Wang X, An Z, Yu X 2022 · Surg Obes Relat Dis | meta-analysis | supports | high | 21 population cohorts (2.86M): MACE RR 0.53, MI RR 0.40, stroke RR 0.60, CV death RR 0.43. |
| Obeso-Fernández J, Millan-Alanis JM, Sáenz-Flores M, Rodríguez-Bautista M, Medrano-Juarez S, Oyervides-Fuentes S, Gonzalez-Cruz D, Manzanares-Gallegos DM, González-González JG, Rodríguez-Gutiérrez R 2024 · Surg Obes Relat Dis | meta-analysis | supports | high | 16 studies (179k) T2D: any CV event RR 0.56, MI RR 0.46, heart failure RR 0.29, CV mortality RR 0.31. |
| Szewczyk J, Grzyb I, Smolinska A, Boloz M, Krawczyk P, Watek Z, Lysynkiewicz K, Haba S, Dapkiewicz E, Gasowski D 2026 · Cureus | observational | supports | low | A narrative review of literature published mainly between 2020 and 2025, found through PubMed/MEDLINE and Google Scholar searches. It reports that 'observational studies and meta-analyses further suggest that, compared with conservative treatment, bariatric surgery is associated with lower rates of major adverse cardiovascular events (MACEs), coronary artery disease (CAD), heart failure, myocardial infarction (MI), stroke, and all-cause mortality.' The review summarises other researchers' studies rather than following patients of its own, and the abstract gives no effect sizes. |
| Stupalkowska W, Henney AE, Riley DR, Sheu EG, Alam U, Cuthbertson DJ 2026 · Diabetes, obesity & metabolism | observational | supports | moderate | TriNetX retrospective cohort of MASLD+T2D patients comparing MBS vs semaglutide; MBS associated with reduced MACE (HR 0.51, 95% CI 0.38-0.67) and heart failure (HR 0.41), despite higher risk of major adverse liver outcomes for RYGB. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.